Jiuzhitang Co., Ltd Announces Clinical Clearance for Volagidemab in Type 1 Diabetes
China-based traditional Chinese medicine (TCM) giant Jiuzhitang Co., Ltd (SHE: 000989) has announced that volagidemab...
Company
Shenzhen Chipscreen Biosciences Receives NMPA Approval for Chiauranib Clinical Study
China-based biopharmaceutical company Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has received approval from the...
Innovent Biologics Halts Subscription Agreement with Lostrancos Ventures
China-based Innovent Biologics, Inc. (HKG: 1801) has announced the decision not to proceed with a...
AstraZeneca’s China President Leon Wang Confirmed to Assist in Investigation Amid Fraud Allegations
On October 29, 2024, just hours after celebrating a business school anniversary on social media,...
Novartis’ Trispecific Antibody PIT565 Secures NMPA Approval for Clinical Trial
Swiss pharmaceutical giant Novartis (NYSE: NVS) has received acceptance for its clinical trial application for...
Shenzhen Chipscreen Biosciences’ Tivozanib Secures NMPA Approval for ES-SCLC Phase III Trial
Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) has announced that the National Medical Products Administration...
Humanwell Healthcare Receives NMPA Approval for Compound Sodium Lactate Ringer’s Injection
Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has received approval from the National Medical Products...
MSD Reports 4% YOY Revenue Increase in Q3 2024, Led by Pharmaceutical Sector
US pharmaceutical giant Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) has released its financial...
Regeneron Pharmaceuticals Reports 11% YOY Revenue Growth in Q3 2024
US-based Regeneron Pharmaceuticals (NASDAQ: REGN) has reported its financial details for the third quarter of...
AbbVie Partners with EvolveImmune to Develop Immunotherapies for Cancer
US pharmaceutical company AbbVie (NYSE: ABBV) has entered into a collaboration and option-to-license agreement with...
CARsgen Therapeutics’ Suspended CAR-T Therapies Get FDA Green Light to Resume
The US Food and Drug Administration (FDA) has removed the suspension on clinical studies for...
AIM Vaccine Submits Market Filing for 13-Valent Pneumococcal Conjugate Vaccine in China
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the submission of a market filing...
Eisai and Biogen Complete BLA Submission for Alzheimer’s Drug Leqembi to FDA
Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have jointly announced the completion...
Jenscare Scientific’s LuX-Valve Plus Shows Positive One-Year Results in TRAVEL II Study
Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced the...
Biogen Reports Q3 2024 Sales Dip, Raises Full-Year Guidance
US biotechnology company Biogen Inc. (NASDAQ: BIIB) reported global sales of USD 2.466 billion for...
Tasly Pharmaceuticals Gets FDA Approval for Acute Ischemic Stroke Cell Therapy Clinical Study
China-based Tasly Pharmaceuticals (SHA: 600535) has announced that it has received approval from the US...
HutchMed to Receive $20 Million Milestone Payment from Takeda for Fruzaqla Sales
China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) is poised to receive a USD 20...
Zhejiang Huahai Pharmaceutical Gets New Zealand Approval for Asthma Bispecific Antibody Trial
Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced receiving clinical trial approval in New...
Youcare Pharmaceutical Group Gets NMPA Approval for YKYY015 Phase I Study
China-based Youcare Pharmaceutical Group (SHA: 688658) has announced that it has received approval from the...
Innovent Biologics Reports Q3 2024 Sales Exceeding RMB 2.3 Billion, Up 40% YOY
China-based Innovent Biologics Inc., (HKG: 1801) has announced product sales exceeding RMB 2.3 billion (USD...